Sugi Predict

Sugi Predict / Compounds / SCHEMBL3384480

SCHEMBL3384480

SCHEMBL3384480

O=c1[nH]c2cc(F)c(F)cc2c(N[C@@H]2CN3CCC2CC3)c1-c1nc2ccccc2[nH]1

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 17/20 0.81
▸ PRKD3 O94806 3/20 0.71
▸ PRKCG P05129 3/20 0.71
▸ PRKCB P05771 3/20 0.71
▸ PRKCA P17252 3/20 0.71
▸ CCNA2 P20248 3/20 0.71
▸ PRKCH P24723 3/20 0.71
▸ CDK2 P24941 3/20 0.71
▸ PRKCI P41743 3/20 0.71
▸ PRKCE Q02156 3/20 0.71
▸ PRKCQ Q04759 3/20 0.71
▸ PRKCZ Q05513 3/20 0.71
▸ PRKCD Q05655 3/20 0.71
▸ PRKD1 Q15139 3/20 0.71
▸ AURKA O14965 1/20 0.53
▸ PDGFRB P09619 3/20 0.49
▸ FGFR1 P11362 3/20 0.49
▸ KDR P35968 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379145 1.00 CHEK1 (0.81) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL14795595 0.94 CHEK1 (0.77) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL14796254 0.94 CHEK1 (0.77) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3383850 0.92 CHEK1 (0.75) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3384816 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15911473 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15910766 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15910802 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3382817 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15911148 0.91 CHEK1 (0.72) CHEK1PRKD3PRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762194-B2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS CHIRON CORPORATION 2004-07-13 — — US claimed
US-20040006101-A1 Quinolinone derivatives CHIRON CORPORATION 2004-01-08 — — US claimed
EP-2762475-A1 Pharmaceutically acceptable salts of quinolinone compounds and their medical use Novartis Vaccines and Diagnostics, Inc. (US) 2014-08-06 — — EP disclosed
EP-2573079-A2 Benzimidazole quinolinones and uses thereof Novartis Vaccines and Diagnostics, Inc. (US) 2013-03-27 — — EP disclosed
EP-1497287-B1 Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-11-24 — — EP disclosed
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 — — US disclosed
US-20100184754-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-07-22 — — US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 — — US disclosed
US-7598268-B2 Quinolinone derivatives NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-10-06 — — US disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 — — US disclosed
US-20080070906-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-03-20 — — US disclosed
US-20040092535-A1 Benzimidazole quinolinones and uses thereof CHIRON CORPORATION 2004-05-13 — — US disclosed
US-20040006101-A1 Quinolinone derivatives CHIRON CORPORATION 2004-01-08 — — US disclosed
WO-2003087095-A1 QUINOLINONE DERIVATIVES CHIRON CORPORATION (US) 2003-10-23 — — WO disclosed
US-20030158224-A1 Quinolinone derivatives CHIRON CORPORATION 2003-08-21 — — US disclosed
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 — — US disclosed
EP-1317442-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
US-20030028018-A1 Quinolinone derivatives CHIRON COPORATION 2003-02-06 — — US disclosed
US-20020107392-A1 Quinolinone derivatives NOVARTIS AG (CH) 2002-08-08 — — US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070906-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3447/4885PRKD3 4347/4885PRKCG 4647/4885
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 CHEK1 2358/4885PRKD3 3788/4885PRKCG 3175/4885
US-20030028018-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-20030158224-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-20020107392-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-20100184754-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3447/4885PRKD3 4347/4885PRKCG 4647/4885
US-20040092535-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 CHEK1 2295/4885PRKD3 3848/4885PRKCG 3401/4885
US-20040006101-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.